Earnings
Taysha Plans To Withhold Rett Results Until FDA Reviews Its Earlier Filing Case
Six-month results could bring an approval application forward by at least two full quarters, management said.
Taysha Gene Therapies (TSHA) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
Earnings
Six-month results could bring an approval application forward by at least two full quarters, management said.
SEC Filings
Commercial-scale manufacturing validation is complete, with interim trial results and FDA pathway feedback expected in early 2027.